Because it is well known that patients having tumors with breast cancer 1 (BRCA1)/BRCA2 somatic mutations or loss benefit from PARP inhibitors, patients with mutations of these 2 tumor-suppressor genes might be therapeutic targets to be investigated for treatment, as demonstrated in our study.9 Despite the negative association found in our study between BRCA2 mutations and lymph node metastasis, which is a poor prognostic indicator, Xie et al45 reported a higher rate of mutations in the BRCA1/2 gene in CRCs with lymph node metastasis. This evidence concerns the gene BRCA2 and metastatic malignant neoplasm in the lymph nodes.